Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
US9388249B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9388249-B2 |
| Application number | US-201414265416-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2014 |
| Priority date | Jul 10, 2006 |
| Publication date | Jul 12, 2016 |
| Grant date | Jul 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody that binds to CD73, comprising: a heavy chain variable region CDR1, CDR2, and CDR3 defined by SEQ ID No: 468, SEQ ID NO: 469, and SEQ ID NO: 470, respectively, and light chain variable region CDR1, CDR2, and CDR3 defined by SEQ ID No: 472, SEQ ID NO: 473, and SEQ ID NO: 474, respectively; or a heavy chain variable region SEQ ID NO: 467 and a light chain variable region SEQ ID NO: 471. 2. An isolated nucleic acid molecule, which encodes the heavy chain variable region and/or the light chain variable region of the antibody according to claim 1 . 3. A vector including the nucleic acid molecule according to claim 2 in a form capable of being expressed. 4. A transformant into which the nucleic acid molecule according to claim 2 is introduced. 5. A cancer therapeutic agent comprising the antibody according to claim 1 as an effective ingredient. 6. A reagent for examining or studying cancer comprising the antibody according to claim 1 .
Assignees
Inventors
Classifications
against translation products of oncogenes · CPC title
Liver or Pancreas · CPC title
against receptors, cell surface antigens or cell surface determinants · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9388249B2 cover?
- The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention fu…
- Who is the assignee on this patent?
- Univ Fujita Health, Amano Enzyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).